Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There's this remarkable feature on Twitter called Unfollow... That's likely the best solution to the Twitter BullSh*t you describe.
Which way do you want it? ALL sales data is "unverifiable" until documented in the quarterly filings. If the CEO reported actual sales figures, they would still be unverifiable until the filings.
The CEO previously reported sales figures on a monthly basis, then a major client failed to pay, and he was accused by some as lying and deceiving shareholders. I don't blame him for choosing to not report actual sales numbers until the filings. All he tells us now is the direction and relative magnitude, which is all we need to know. If one believes the CEO and CFO are intentionally lying to shareholders, there's this little feature in every brokerage firm called the SELL button. I suggest using that.
CEO has been very transparent with shareholders that most major media outlets aren't really interested in a small company like Todos until the phase 2 data is released. Perhaps you missed the interviews on Yahoo News and Fox News with Stuart Varney... you know, the MINOR news outlets. Also, CEO has stated they company has lined up MAJOR news outlets following the trial data release. From these major news outlets viewpoint, that's the appropriate time to start reporting on a small company that hardly anyone has heard about, because they will have MAJOR NEWS TO REPORT!!!
Shareholders are not getting tired of this pattern. Shareholders are appreciative our company is so open and transparent. Some traders/flippers, however, will never be honest about their true intentions and their "outlook" changes depending on what side of the flip they're on. Most here can easily spot a flipper and put them on ignore.
Everyone should trust their due diligence and conviction in what and why they invested. Don't allow spread of fear and disinformation deter your goals. GLTA
Post updated with new reply.
Not only is Don Huffman the acting CEO of Amarantus, he has been acting CEO since 4/1/21.
From page 26 of the Amarantus Quarterly Filing
In a double-blinded study like the Tollovir trail, neither the patients nor the researchers/doctors know which patients are receiving drug or placebo. The statistician should also be blinded during data analysis as knowing the details can cause bias in analysis of results. The trial should only be unblinded after statistical analysis is complete for the greatest degree of eliminating potential bias.
It would be hard to fathom anyone in the company knowing the trial outcome at this point, because that would imply patients or researchers were not truly blinded. This trial cost the company millions of dollars and has taken a long time. Any evidence of unblinding before the final analysis is complete would seriously jeopardize the validity of the trial results.
Two patients had died at the point they halted the trial. While everyone suspects the deaths were in the placebo group, no one can be sure until the trial is unblinded following statistical analysis. Based on the 2020 Tollovir observational study in moderate to severe hospitalized patients, it's unlikely any of the Tollovir patients died because of the mechanism of action in treating Covid. Whatever the interim data reveals, per Gerald's comments a phase 2/3 pivotal trial will begin in Q1 2022 using all they've learned in this study.
I'm not a medical expert, but the above statements are based on what I've read and learned about clinical trials since becoming a Todos shareholder.
No reason for concern. There was some Twitter chatter last night that another poster misinterpreted and made some posts on several other message board that Gerald was stepping down as CEO. Totally bogus and was quickly corrected. That's probably where he got the info.
But it does make one question why he didn't see the corrections on those boards (easy to see), and if he did, why he chose to post the fake news here anyway.
2022 is going to be a great year for Todos investors.
Agreed, and Gerald has stated this as well in multiple interviews and on the investor conference call. They are taking a very strategic approach to their FDA application and the data being presented. Plus they've hired exceptional expertise to help with this.
Nice comment about the Hoover Dam. Tollovid revenues are soaring, so expect same for Tollovid wherever it finds approval.
Stamford University, the one near Sam Framcisco. LMAO
Looks like someone has their wires crossed about Gerald and is spreading more fake news. Par for the course. Gerald Derangement Syndrome clouds and confuses the mind.
Gerald is not going anywhere. He will remain CEO of Todos through the uplist and all the great things that follow. And FDA will approve Tollovir. They have no choice when the data shows how effective it is in preventing Covid deaths even among moderate to severe hospitalized patients.
Share Structure Update - 12/31/21
35,181,965 shares added since last update on 12/23/21.
https://www.otcmarkets.com/stock/TOMDF/security
I'm well aware of MONI's history. Same story, new management/new business model and new carrot dangled in front of shareholders, always just beyond reach.
I didn't say anything about expectations of massive MONI revenues. I understand MONI is in a start-up phase after the management change. I stated in an earlier post I'm glad I sold MONI at .053 before it tanked further and moved those funds to another OTC investment generating millions in revenue and planned uplist to Nasdaq in Q1 2022. Nothing but hype here, just like the last 9 years.
Hope it works out for you, but there are better OTC investments with far greater potential than the "Girl Power" and speculated Blue Blood backing.
True, Rome wasn't built in a day. Apparently, 9 years later, MONI still hasn't been built. 22 cents to less than 2 cents... that's a lot of building. Looks more like building a tunnel deeper and deeper into the Earth. Tunnel to China, perhaps.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=81637191
Glad that false narrative has been put to rest after seeing it posted multiple times. Paints quite a different picture when it's shown everyone's posts got taken down together when the website shut down, and Gerald wasn't deleting his posts, as claimed.
Only 500% for those buying in at the pathetic .015 level. What about those who bought into the hype and purchased shares much higher? I suppose they'll have to wait until 2023.
Agree 100%. MONI driven by hype. Glad I exited MONI before the large drop and invested proceeds in another OTC company with millions in revenue, dramatically growing business model, major near-term catalysts and Nasdaq uplist in Q1 2022.
The Chairman's Blog was a website hosting commentary from many CEOs. The site no longer exists. Gerald erased it from the internet? LMAO
About The Chairman's Blog
https://web.archive.org/web/20150913185423/http://www.thechairmansblog.com/about/
Contributors to The Chairman's Blog
https://web.archive.org/web/20150913221854/http://www.thechairmansblog.com/contributors/
I suppose all of these other contributors also decided to "erase" their blog posts. Perhaps Gerald "erased" their posts along with his own. I guess when the entire website was shut down and everyone's posts vanished in an instant... we'll just overlook that little fact in order to support the false narrative.
Doesn't matter. When someone over invests in a high risk penny stock hoping for riches, that is their decision, not the CEO.
I'm not sure what current info you're referring to. Todos Medical's web site has always maintained current info for shareholders. If you're referring to sites like Yahoo Finance, that info is often outdated. It is the site's responsibility to keep their data current, not the company's responsibility.
I wasn't trying to address all comments toward you. I'm just tired of seeing investors expecting so much from such a small company like Todos. Investors notice little things like tape, and I emailed Gerald about it and it was fixed by next presentation. However, in the big picture, I can overlook little things like that as long as they get the big things right. I'm sure with every CEO coming into the presentation setting and taping up their logo on the background, most never give it a second thought that investors would notice and complain about the tape being visible.
Again, when you have 100 things to get done each day, and you get 97 of them done right, I can lighten up on the 3 that didn't get addressed. These people are working hard to make this company a success. I just don't want to see shareholders get overly critical because of unrealistic expectations.
Exciting times ahead.
Yeah, missiles were being launched into Israel every day and shareholders were bitching and moaning about the quarterly filing being late. It is hard for me to comprehend the level of complete and utter disregard some folks have for others in what was a literal war zone at the time. Screw the goal of trying to protect one's family with missiles flying... let's get to the office and get those financials reviewed so our damn shareholders won't be upset with being late in reporting.
And yes, our CEO is constantly pressured to provide dates to impatient shareholders who bitch if no dates are given, and bitch if dates are given but have to be adjusted. All this from a small company with 14 employees (according to LinkedIn) who are advancing their cutting edge products on multiple fronts. Investors are upset because the phase 2 interim data has been pushed out another few weeks. The reasons have been explained in detail in interviews, presentations, and Twitter responses. But investors want that data and want it now. Otherwise, it's time for doubts that the data may not be that good. Bitch if the data gets pushed out, and bitch if the data is presented on the original schedule and is rejected by regulators because the company didn't take the time to properly set up biomarker endpoints that emerged during the conduct of the trial or take into account events that transpired since the original data release date. No investor would forgive the CEO for screwing that up. It's a no-win scenario for Todos employees.
Perhaps I just woke up in a foul mood, but in reading investors comments on multiple sites, I'm ready to start suggesting investors who can't handle the delays and understand all that's going on within this little company should sell their shares and invest in Pfizer. I'm sure that with their thousands of employees they meet all of their deadlines, and investors won't have anything to complain about regarding timelines and expectations.
I don't give a crap about expected deadlines being missed if the reasons are valid and honest. I have no reason to believe Gerald has been anything but honest and forthcoming with shareholders. This is one of the most transparent OTC companies you will find, and they appear to have done their due diligence in the regulatory space they will be addressing with their data. However, with former AMBS investors who lost money grinding their axe against Gerald here daily, it's easy to get all caught up in missed expectations and start to question motives when dates are extended or revised. Why would anyone remain invested in a company where they believe the CEO is deceiving shareholders?
Investors should be confident in what they own, and not let naysayers with personal agendas against the CEO shake their confidence. If a shareholder is having doubts, I suggest they sell and move on. Or at least spend some time revisiting recent conference calls and presentations to try to understand all that's going on in this tiny little company trying to compete against the likes of Pfizer and Merck. And for those who believe delays are causing us to miss the boat... you're clearly not staying informed. Covid is NOT going away. I'd rather the company take the time to get it right with Tollovir than rush the trials and data analysis and get it wrong. Getting it right will greatly benefit shareholders.
Good advice. Also, the 30-day window applies to all accounts. If one sells in a taxable account and repurchases in another account, even a tax-deferred account like an IRA, the wash rule still applies. I discovered this a number of years ago after I had done exactly that and had to file an amended return to correct for the wash sale. IRS publications discussing wash sales even gave this example involving an IRA repurchase.
Good deal. I'll probably order again before the holiday special ends just to stock up at the lower price. It certainly can't hurt to have 3CL protease inhibitors in our body with the Omicron variant raging everywhere. And the more I read about long Covid and the emerging data on how the virus hides out in the cells of various organs long after the initial exposure, it's probably a wise move to start the daily treatment and figure out how to work it into the budget. I really don't want to risk another vaccination or booster.
I'm aware of the Amarantus story. I'm also aware that some investors became so enamored with Gerald and the Amarantus potential they invested far more than they should have in a start-up penny stock. All one has to do to read through the AMBS posts back then to see who was heavily invested - hook, line and sinker invested, leaving no room for the possibility of things not going as planned. One poster even claimed to own a multiple of 5 times what the CFO owned, or about 3.3M shares at that point. That's a lot of investment dollars given the share price back then. That decision is on the investor, not the CEO.
Most of those investors apparently took ownership of their mistakes and don't continue to post years later continuing to blame the CEO. They may still blame the CEO, but at least they've moved on and don't churn it up in their consciousness on a daily basis. I applaud them.
Removing the Chairman's Blog posts... I imagine that was done at the request of the attorneys. As I recall reading through the AMBS posts, some other posters were having to adjust their posting based on the advice of their attorneys. So that should ring a bell.
My advice to anyone investing in any single investment (penny stock or otherwise), is to invest no more than you're comfortable losing. Even when things seem like a slam dunk, unforeseen events happen that derails even the best laid plans. Manage your exposure accordingly.
That being said, I'm managing my exposure to Todos and not investing every penny I have here, regardless of how promising the story and the assets are. But I do have a bottle of Tollovid ready and have started taking Tollovid Daily.
I'm exploring options to order in bulk from Alibaba to keep my per-bottle cost at a minimum.
Pennyes, your info is a little outdated. Todos Medical is a completely separate company than Amarantus Biosciences (AMBS), not a subsidiary. Todos Medical is based in Israel but has an office in New York City.
In December 2018, Todos and Amarantus partnered to form Breakthrough Diagnostics to focus on further development of the LymPro blood test.
https://investor.todosmedical.com/news-events/press-releases/detail/10/todos-medical-enters-into-joint-venture-agreement-with
In June 2020 Todos completed the acquisition of the Breakthrough Diagnostics joint venture and took sole ownership of LymPro. This acquisition awarded Amarantus 78 Million shares of Todos Medical. At the time the accounted for 49% of the outstanding TOMDF shares.
https://investor.todosmedical.com/news-events/press-releases/detail/62/todos-medical-completes-acquisition-of-breakthrough
However, during the remainder of 2020 and 2021, Todos issued more shares to fund operations, trials, research, and transferring all existing convertible debt to a handful of reputable venture capital firms who were committed to the long-term growth and eventual uplist to NASDAQ. As more shares were issued, the 49% value dropped. At current TOMDF share count, the 78 Million shares owned by Amarantus is approximately 8.3% of the outstanding shares.
Todos Medical began in Israel in 2010 and is not related to the Amarantus corporate structure in any way other than the joint venture and acquisition of Breakthrough Diagnostics as described above. They both had the same CEO until Gerald stepped down from Amarantus and an interim CEO was announced until a new CEO can be hired. Gerald has been focused on Todos but his plan is that once Todos uplists to NASDAQ then Amarantus will have the ability to sell their Todos shares to pay off debt and fund continued operations of the assets they still hold. This would be a rebirth of Amarantus and seems like a good plan as long as Todos executes well on their plan.
Amarantus Biosciences and Todos Medical are completely separate companies except for the paths crossing as mentioned above. Todos had a number of diagnostic tests in the works prior to involvement with Amarantus and acquired the Videssa breast cancer test with the acquisition of Provista Labs. Amarantus had nothing to do with that transaction.
I would expect a major press release announcing the data prior to the conference presentation. After the conference, expect follow through on the media coverage Gerald spoke about on the investors conference call. They should know the trial results by mid-January and have time to line up the interviews.
I plan to continue to load up on cheap shares in the interim. There should be updates on Videssa sometime mid-January.
*** News Flash *** Every company hides behind their forward-looking statements. If they didn't have this protection they would never be able to release anything to shareholders other than routine financial filings. If a CEO makes statements in press releases, conferences, interviews and blogs, those are all protected as forward-looking statements and investors should realize those statements outline what the company is trying to accomplish or their strategy in moving the company forward. They are not set in stone and are subject to change. Plans sometimes don't work out. Decisions made in good faith can turn out to be bad decision based on lack of knowledge or lack of experience.
Investors who bet the farm based on things stated in press releases, conferences, interviews and blogs are responsible for their decision. Gerald isn't responsible for a person's greed where they bet the farm on a penny stock investment hoping for riches. That's on the investor. Expectations and the risk a person makes with their investments are clearly the responsibility of the investor. Unfortunately, some people still don't understand the difference.
Sad, but true.
Picked up more TOMDF shares today, lowering the average purchase price a little more. I plan to continue to load until data is released.
Lots to like about this company and those working hard to make it a success, despite the opinions of some who are still living in the past. Accepting responsibility for bad investment decisions is a sign of maturity. Blaming others is what children do.
Coming together nicely? So glad I exited this turd at 0.053 instead of holding. A decade of unfulfilled promises and "just around the corners" followed by "3+ years in the making". No thanks.
Looks to be headed towards the 1 cent level, which would be appropriate since it is a penny stock. Buying opportunities abound. How much will someone sink into a turd before they realize it's a turd?
And it is reported Gerald went so far as to lose money someone inherited from their mother and invested it in the penny stock AMBS. Unbelievable how dastardly some CEOs can be.
Fortunately, the investor learned their lesson and won't invest again with Gerald. They've found much more reputable penny stock CEOs to invest with where speculation of future revenue inspire all kinds of dreams of riches. One certainly wouldn't want to invest in a company like Todos where revenues actually exist and are growing, with major catalysts on horizon.
First, this is an OTCQB penny stock. There are many here, including speculators and market makers, who have short-term motives and are flipping or shorting the stock. It can be frustrating for longs who want to see a return on investment in a reasonable time frame. But as the CEO has stated numerous times in response to investor questions about share price, he can only focus on execution of the business plan. There is an expectation of greater appreciation in share price when good news hits once the stock trades on NASDAQ.
Second, reporting record testing sales isn't the same as seeing those number in the quarterly earnings report. For many folks, that is what they focus on. Gerald reported record sales for testing supplies last year, and then $7M of those revenues failed to be collected due to non-payment by the customer. That is still in everyone's mind, so the focus on SEC filings is understandable and the news alone doesn't move share price.
I picked up more Todos shares today, and expect to pick up more this week and next week. I previously stated I was done buying shares, but with the downward turn in share price it's hard to ignore when I firmly believe the phase 2 data will be very strong. I expect a partnership or buyout offer, perhaps competing offers, to be announced after the data is made public.
Good luck. Exciting weeks and months ahead. My outlook hasn't changed.